Subject Index

ABL gene, TSC linkage to, 224, 265, 267, 269, 271–272, 280, 304
ABL locus, 267, 272
  lod scores for, 269, 271
  polymorphism in, 265
  and TSC1 locus, 280, 304
ABO locus
  and chromosome 9 gene map, 292–293, 295
  lod scores for, 380
  and RFLP analysis, 292
  TSC linkage to, 224, 284, 304, 316, 384
  and TSC locus identity, 257, 265–266, 271
Acoustic neuroma, 328, *see also* Schwannomas
  and chromosome 22 locus, 339–342
  coexistence with NF2, 338–340
  frequency of, 342
  molecular genetics of, 339–340
Adenoma sebaceum (AS), 23, 28–29, 196, 214, 228–230, 257, *see also* Facial angiofibroma
  in pulmonary TSC, 61
  in retinal hamartoma diagnosis, 22
  stroma cells of
    abnormal gene expression in, 228–241
    chromosome disarrangement in, 237, 241
    C-mitosis in, 236–237, 241
    DNA content of, 234–236, 240
    pleomorphism in, 231–241
  in TSC, 1, 17, 43, 61, 72
Albinism, allelic heterogeneity in, 348
Alzheimer-type changes, in TSC tubers, 140
Aneurysms, in TSC, 65–67
Angiofibromas, 247
  molecular biology of, 372
  origin of, 280
Angiomyolipomas, 3, 36, 41–46, 101, 196, 318
  complications of, 106–107
  and hepatic hamartoma, 109
  monitoring of, 107
  origin of, 280
  renal, 4–5, 36, 41–46, 71
  renal carcinoma association with, 106
  renal cysts association with, 108
  as sole TSC manifestation, 42
  and TSC mortality, 375
Anti-oncogene, *see* Tumor suppression gene
Arrhythmia
  and cardiac rhabdomyoma, 52, 58, 257
  from intramural hamartomas, 3
AS, *see* Adenoma sebaceum
Ataxia, in cerebral TSC, 2
Ataxia telangiectasia, chromosome 11 locus for, 279
Atopy, 345
Autism
  diagnosis of, 179
  pathogenesis of, 15
  in TSC, 2, 9, 12, 14–15, 382–383
Autism behavior checklist (ABC), 382–383
Azotemia, in cystic disease, 36

Batten's disease, 345
Bourneville's disease, *see* Tuberous sclerosis complex
Brain tumors, in TSC, 378–379

Cadherin, 173–175, 177
N-Cadherin, 174–175
  and dorsal root ganglia, 162
T-Cadherin, and neural crest cell migration, 160
CAM, *see* Cell adhesion molecules
A-CAM, *see* N-Cadherin
L-CAM, *see* Liver cell adhesion molecule
N-CAM, *see* Neural cell adhesion molecule
Cardiac rhabdomyoma, 2–5, 46, 50–56, 58–60, 96–97, 124, 245, 247, 317, 355–356, 367
  age-dependent expression of, 5
  and arrhythmia, 52, 58, 257
  imaging of, *see also* Computerized tomography; Magnetic resonance imaging; Ultrasonography
    by CT, 96
    by echocardiography, 50–56, 58, 96
    by MRI, 96
    by ultrasonography, 96
Cardiac tumors, in TSC, 58
CCT, *see* Computerized cranial tomography
Cell adhesion molecules (CAM), 212
  in cell proliferation, 280
  and chromosome 11, 249
  and developmental defects, 179

in disease, 176
in embryogenesis, 172, 174–175, 178–180
families of, 172–174
immunoglobulin homologies to, 172–174
induced expression of, 174–175
as infectious agent receptors, 179–180
in morphologic maintenance, 172
in neuromuscular system, 178
and transformed cells, 175–176
in tumors, 176–178
Cell-cell adhesion, in neural crest cell development, 162
Cell-ECM adhesion, hexabrachion mediation of, 223
Cell lineage control, of neural crest cell differentiation, 163–164
Cell surface receptors, 149, *see also* Fibronectin; Glycoproteins; Integrin; Proteoglycans
and angiofibroma origin, 280
and angiomyolipoma origin, 280
in ECM, 160, 162
Central nervous system (CNS) tumors, in VHL, 333
CEPH families, and polymorphic DNA markers, 384
CEPH reference pedigrees, and chromosome 11, 258, 292
Cerebral hamartomas, 4
in vivo detection of, 8–10, 81–92
Cerebral TSC lesions, histogenesis of, 187–193
Chemodectoma, mendelian inheritance in, 215–216
Chromosome deletions, and heritable disorders, 243
Chromosome 3
karyotype studies of, 334
and renal cell carcinoma genes, 335–336
and VHL gene locus, 333–336, 363
Chromosome 9
hexabrachion gene on, 224
mutants of, 352
and TSC, 4, 224, 258–272, 284, 292–295, 299–305, 310–313, 344, 352, 355, 384–385
Chromosome 11
mutants of, 352
and TSC, 4, 258, 274, 284, 292–295, 299–304, 310–313, 316, 344, 352, 355
TSC2 gene locus on, 274, 299–304
Chromosome 14, and TSC, 284, 293, 316
Chromosome 17
EVI2 locus on, 328
genetic mapping of, 320–322
NF1 gene locus on, 319–320, 322, 327–329
translocation breakpoint region of, 319–320
and TSC, 319–322, 327–329
Chromosome 22
and acoustic neuroma/meningioma inheritance, 342
anomaly in, 248–250
markers on
and acoustic neuroma, 339
and meningioma, 339
and TSC, 248–250, 339, 342
and tumorigenesis, 339
Chronic granulomatous disease, 333
chromosome deletion in, 243
Clear cell carcinoma, 3
CNS, *see* Central nervous system
Computerized cranial tomography (CCT), *see also* Computerized tomography
abnormalities detection by, 112–113
in TSC diagnosis, 112–113, 350, *see also* Diagnostic criteria
in TSC evaluation, 113–114, 117–121, 285
Computerized tomography (CT), *see also* Diagnostic criteria
angiomyolipoma monitoring by, 107
disadvantages of, 52
intracranial TSC evaluation by, 81–86, 126, *see also* Computerized cranial tomography
in pulmonary TSC, 3
in retinal hamartoma diagnosis, 22
SEN detection by, 92
Computerized tomography (CT) imaging
of cardiac involvement, 96
in cardiac patient evaluation, 110
of cerebral hamartomas, 8
of hepatic involvement, 108–110
of pulmonary involvement, 95
of renal involvement, 98, 101, 106–108
in TSC evaluation, 317
Connective tissue nevi, *see* Shagreen patches
Cortical tubers, 4, 46, 86, 119, 124, 131–134, 212–214, 225, 246–247, 257, 279, 367
EEG/MRI findings in, 10–11
EM findings in, 140–147
and epilepsy, 13–14
and neurologic TSC manifestations, 8, 10
and retardation, 142
ultrastructural morphology of, 214
Cosmid clones, of NF1 locus, 319–320, 322, 327–329
CT, *see* Computerized tomography
Cystic disease, *see also* Renal cysts
and azotemia, 36
and hypertension, 36

Cystic fibrosis, 333
allelic heterogeneity in, 348

Dementia, in cerebral TSC, 2
Dental enamel pitting, in TSC, 367–368
Diagnostic criteria
for TSC, 14, 26–34, 50, 71, 123–124, 247, 257, *see also* Computerized tomography; Electroencephalogram; Magnetic resonance imaging; Ultrasonography
Gomez's, 14, 71, 257, 285, 360
Vogt's triad, 17, 257
DNA content, of AS stroma cells, 234–236, 240
cDNA library, from TSC cells, 373–374
DNA linkage analysis, of VHL gene locus, 333–336
Duchenne's muscular dystrophy, 333
chromosome deletion in, 243
Dysplasia, in TSC, 65, 137, 140, 147

Echocardiography
in cardiac rhabdomyoma assessment, 50–56, 58
in TSC diagnosis, 3, 96, 307, 365
EEG, *see* Electroencephalogram
Electroencephalogram (EEG)
foci localization by, 8–15, 26, 28
and seizure classification, 8–9
Electron microscopy (EM)
and GFAP expression monitoring, 240
in TSC diagnosis, 30
and TSC findings, 140–147
EM, *see* Electron microscopy
Embryogenesis, CAMs in, 174
Epilepsy, 126, 265, 367, *see also* Seizures
and mental retardation, 13–15
MRI findings and, 117
in TSC, 8–9, 12–15, 17, 43, 72, 228
EVI2
amino acid sequence of, 323
cDNA clones encoded by, 322
genomic cosmids for, 322, 327–329
genomic organization of, 323–327
locus of
NF1 locus linkage with, 322
RFLP and, 322
EVI2 mRNA expression, in NF1 tissues, 322
Extracellular matrix (ECM), 220
components of, 149–157, 222
FN in, 149, 156, 160
molecules in, 167
cell surface receptors for, 162
and neural crest cell migration, 159–162, 166–168
and TSC pathogenesis, 361–362

Facial angiofibroma, 1–5, 26, 46, 66, 71–72, 124, 126, 196, 211, 214, 231, 367
age-dependent expression of, 5
Fibronectin (FN), 172, 221, 223–224, 239, 372, *see also* Glycoproteins
abnormally glycosylated, 361–362
alterations in, 149–151, 155–157
in ECM, 149, 156, 160
gene for, 224
and glycoprotein interaction, 280
and neural crest cell migration, 160, 162, 168
FN, *see* Fibronectin
Forehead plaques, 4, 124, 126
Foster-Kennedy syndrome, 17
Friedreich's ataxia, 345

Gene mapping
of chromosome 17 translocation breakpoint
cosmid probes and, 320–322
PFGE and, 320
MAP90 program for, 299, 304
maximum lod score method for, 299–304
multipoint analysis for, 299
negative lod score method for, 299–304
for TSC, 298–304
Genetic counseling, for TSC, 30, 117–121, 126–127, 265, 271, 284, 365
Genetic linkage analysis, *see also* Linkage analysis
of NF1 locus, 328–329
cosmid clones and, 319–320, 322, 327–329
Germinal heterogeneity, in TSC, 349
Germline mosaicism, 356
GFAP, *see* Glial fibrillary acidic protein
Giant cell astrocytomas, *see* Subependymal giant cell astrocytomas
Glial fibrillary acidic protein (GFAP), 199, 202, 209, 212–214, 230, 232, 239–240
EM observation of, 240
TSC cell distribution of, 372
Glycoproteins, *see also* Fibronectin
alterations in, 149–157
in *Drosophila* nervous system, 279
in ECM, 149, 220–222, 280
and FN interaction, 280
and neural crest cell migration, 168
Gonadal mosaicism, 267–272, 352
Gonosomal mosaicism, 318

Hamartias, 1–4, 141, 280–281
of CNS, 257
Hamartoblastomas, 1–4
Hamartomas, 1–5, 17–23, 26–34, 36–46, 50–56, 58–67, 71–79, 81–92, 94–110, 112–121, 124–126, 132–138,

141–147, 164, 187, 189, 196–199, 211–216, 224–225, 228–241, 245–248, 256–257, 274, 279–281, 318, 349, 355–356, 367, 378, *see also* specific hamartomas
cerebral, 4
in vivo detection of, 8–10, 81–92
of CNS, 257
hepatic, 108–109
ultrasonography of, 108
in NF1, 339
pulmonary, 3, 60–65
female hormones in, 5
rectal, 71–79
renal, 3
female hormones in, 5
ultrasonography of, 365
Hemangioblastomas
in VHL, 333–334
of CNS, 363
Hemangioma, in TSC, 65
Hemoglobinopathies, allelic heterogeneity in, 348
Hemophilia, 357
Heparan sulfate, 149–155, *see also* Proteoglycans
alterations in, 151–157
in cell-ECM interactions, 149
Heterogeneity, 284, 295, 317, 344–352
allelic, 347–348
cosegregation problem and, 350–351
in dominant diseases, 348
gametic, 347, 349
germinal, 347, 349
HOMOG programs for, 266, 269, 272, 309–310
imposed, 347, 350
locus, 308–310, 314, 347–348
at locus level, 352
lod scores for, 266, 269, 271–272
numeric problem and, 350
in TSC, 274–281, 372
clinical classification and, 256–263
in TSC locus, 344
types of, 347–350
in X-linked diseases, 348
Hexabrachion, *see also* Glycoproteins
biochemistry of, 220–221
cell adhesion mediation by, 223
function of, 222–224
gene locus, 224
localization of, 221–222
mutations in, 225
Hexabrachion gene
as TSC gene, 224–225
Homogeneity
HOMOG programs for, 258–261
and chromosome 9, 292–294
and chromosome 11, 292–294
and linkage analysis, 254
multipoint lod scores in, 292–294
Huntington's disease
heterogeneity in, 347, 348–349
homogeneity in, 344
Hyperreninemia, in cystic disease, 36
Hypertension
in cystic disease, 36
in pulmonary TSC, 64, 66
in TSC, 257
Hypomelanotic macules, 4, 50, 66, 79, 126, 281, 285, 367
diagnostic significance of, 28–30, 34
and neural crest, 164
nevus depigmentosus confusion with, 32
retardation association with, 31
in retinal hamartoma diagnosis, 22
seizure association with, 31
types of, 30–34
vitiligo similarity to, 26–28, 32

Imaginary chromosome approach, 309–314
Infectious agents, CAMs as receptors for, 179–180
Integrins, 149, 160, 223
in ECM, 160, 167
and neural crest cell migration, 160, 162, 167

Karyotype investigations, 317
Klippel-Trenaunay syndrome, TSC coexistence with, 79, 94, 98

LAM, *see* Lymphangiomyomatosis
Laminin
and ECM, 167
and neural crest cell migration, 160, 162, 167–168
Linkage analysis
of TSC, 4, 284–295, 344, 365, 384–385
and chromosome 9, 274, 352, 384–385
and chromosome 11, 274, 352, 360
with chromosome 9 mutants, 352
with chromosome 11 mutants, 352
chromosome 11 probes in, 360
for genetic heterogeneity, 243, 252–254, 257–263, 306–314
for homogeneity, 254, 258–263
implications for future, 351–352
LINKAGE programs for, 253–254, 299, 384
LINKMAP multipoint analysis in, 258, 266–267, 292–294
LINKMAP subprogram for, 258
LIPED program for, 253, 266, 292–294, 299
LIPED two-point TSC analysis, 374
lod scores in, 252–254, 258, 292–295, 341

MLINK program for, 292–295
multipoint, 292–293, 384
in NF2 families, 340–341
RFLPs in, 341
of VHL gene locus, 334
Lish nodules, 339
Liver cell adhesion molecule (L-CAM), 173–175
Locus heterogeneity, 312–313
Lod scores
for TSC linkage, 257–263, 265, 269, 271, 300, 341, 380, *see* Linkage analysis
Lymphangiomyomatosis
and TSC mortality, 375
Lymphangiomyomatosis (LAM), 3
in pulmonary TSC, 60–65
age-dependent expression of, 5
female hormones in, 5
treatment of, 65

Magnetic resonance imaging (MRI), 52
in affected parents identification, 118–121
and cerebral TSC diagnosis, 8–10, 119–121
and cortical tuber localization, 8–15
cranial scan by, 126
in evaluation of intracranial TSC, 86–92
findings in TSC, 114
lesions
and autism, 15
and seizures, 15
myelination influence on, 92
and neurologic impairment findings, 114–117, 121
in TSC diagnosis, 96, 112, 285, 317, 365
MAP90 program, and TSC2 localization, 299, 304
Marker genes, *see also* Probes
on chromosome 14, 293
on chromosomes 9/11, 257, 274–275, 292–293, 304
polymorphism of, 262
TSC gene linkage with, 257–263
Maximum lod score method, 299–304
Mendelian inheritance
of multiple endocrine adenomatosis, 215–216
of multiple nevoid basal cell carcinoma syndrome, 215–216
Meningioma, 338
chromosome 22 locus of, 339–341
coexistence with NF2, 338–340
frequency of, 342
gender and, 338
molecular genetics of, 339–340
Mental retardation
CCT lesions and, 113
and epilepsy, 13–15
in TSC, 1–2, 8, 12–15, 26, 43, 72, 142, 228, 257, 380
frequency of, 125–127
C-Mitosis
in AS stroma cells, 236–237, 241
Molecular analysis, of heritable disorders, 243
Molecular biology, of TSC cultured cells, 372–374
Molecular genetics, Southern blot analysis in, 339
Mortality, in TSC, 3, 375–376
MRI, *see* Magnetic resonance imaging
Mulberry cluster hamartoma, 18–19, 21, 23
Multiple endocrine adenomatosis, mendelian inheritance in, 215–216
Multiple nevoid basal cell carcinoma syndrome, mendelian inheritance in, 215–216
Muscular dystrophy, 357
Mutant *Drosophila* phenotype, and ABL mutation, 280
Mutation, in TSC, 274
Mutation disorders
multiple-loci, 345–346
hemophilia/albinism, 346
single-locus, 345
Mutation model, for TSC, 165–168, 192–193
Mutation rate, in TSC, 256–257
Myotonic dystrophy
gametic heterogeneity in, 349
homogeneity in, 344

National Tuberous Sclerosis Association, 285
National Tuberous Sclerosis Registry, 365
N-cells, *see* Neuron-like cells
Negative lod score method, 300, 304
and TSC1 locus, 299–304
Neural cell adhesion molecule (N-CAM), 172, 174–180
and cell-cell adhesion, 162, 176
and dorsal root ganglia formation, 162
gene for
and chromosome 11, 278–279
localization of, 249
as TSC gene candidate, 249, 278–279
molecules homologous to, 177–178
mRNA of
and cell aggregation, 176
and neural crest cell migration, 162, 166
serum levels of
and autism diagnosis, 179
in depressed patients, 179
and schizophrenia, 179
and TSC genes, 280

Neural crest cells
  development of, 162
  differentiation of, 163–164
  migration of
    and ECM, 159–168
    environmental regulation of, 159–160
    FN in, 160, 162, 168
    in vivo perturbation of, 160–161
  origins of, 158
  and SEN links, 164
  and tuberous sclerosis, 164–168
  in vitro ECM interactions with, 161–162
Neuroblastoma, mendelian inheritance in, 215–216
Neurofibromatosis
  homogeneity in, 344
  TSC coexistence with, 79, 94, 98
Neurofibromatosis 1 (NF1), 22, 216, 243, 357, *see also* Phakomatoses
  EVI2 mRNA expression in, 323
  EVI2 role in, 328
  gene for
    and chromosome 17, 319
    cloning of, 319–320
  gene locus of
    cosmid clones of, 319–322, 327–329
    PFGE analysis of, 320, 328
  hamartoma in, 339
  history of, 319
  melanocytes in, 319
  mutation frequency in, 328–329
  neural crest-derived tissue and, 319
  patient-specific mutations in, 327–328
  Schwann cells in, 319
  translocation breakpoint region, 319–329
    cDNA clones in, 322, 327
    characterization of, 322
    genetic mapping of, 320–322
Neurofibromatosis 2 (NF2)
  gene for
    and acoustic neuroma, 341
    isolation of, 341–342
    saturation mapping and, 342
  gene locus of
    Southern blot analysis and, 342
    and tumor suppressor gene, 341
  linkage analysis of, 340–341
  molecular genetics of, 338–342
  penetrance of, 339
  tumor types coexistent with, 339
Neurologic impairment
  CCT findings in, 113
  MRI findings in, 113–117, 121
Neuronal cell migration
  and cerebral lesion histogenesis, 187–193
  and cortical tubers, 279
  in *Drosophila*, 279–280
Neuronal markers, in TSC tissue culture, 202
Neuron-like cells (N-cells), 196–209, 217
  cellular identity of, 211–212
  chromosome complement of, 214
  developmental origin of, 214–215
  and tumorigenesis, 216–217
Neuropsychiatric/psychologic features
  in TSC, 11–15
    EEG foci, 8–11, 13
    MRI lesions, 8–13, 15
NF1, *see* Neurofibromatosis 1
NF2, *see* Neurofibromatosis 2
NIGMS Human Genetic Mutant Cell Repository, 285, 293
NIH Human Genetic Mutant Cell Repository, 316–317
Nonpenetrance, of TSC, 5–6, 192, 271, *see also* Penetrance
North Carolina Tuberous Sclerosis Association (NCTSA), 370–371

Oncocytoma, renal cell carcinoma coexistence with, 41
Ophthalmic TSC manifestations
  nonretinal, 17
  retinal hamartomas, 1–4, 17–23, 61, 66, 367
  vascular changes, 20
  visual loss, 21
Ophthalmoplegia, in cerebral TSC, 2

Pancreatic carcinoma, 363
Pancreatic tumors, in VHL, 333
Penetrance
  of TSC, 1, 263, 274, 292, 295, 299, *see also* Nonpenetrance
    range of, 256–257
    rates of, 257
Peptidoglycans, *see* Proteoglycans
Periungual fibroma, 124, 247, 281, *see also* Ungual fibroma
  germinal heterogeneity in, 349
PET, *see* Positron emission tomographic (PET) scan
PFGE, *see* Pulsed-field gel electrophoresis
Phakoma, *see also* Retinal hamartomas
  in pulmonary TSC, 61
Phakomas, 1, 61, 124
Phakomatoses
  cellular pathology of, 212, 214–216
  VHL disease, 363–364
Pheochromocytoma, 333–334, 336, 363
  mendelian inheritance in, 215–216
  in VHL, 333–334, 336
Pleomorphism, in AS stroma cells, 231–241
Polyps, in TSC, 71–79
Positron emission tomographic (PET) scan, and hypometabolic region detection, 13

Probes, *see also* Marker genes
and chromosome 9 mapping, 266, 269
in linkage analysis, 257–263
Proteoglycans, 149, 151–157, 223, *see also* Heparan sulfate
alterations in, 149–157
in ECM, 149, 157, 160, 168
hexabrachion binding to, 223
and neural crest cell migration, 160, 168
Psychiatric disorders, in TSC, 382–383
Pulsed-field gel electrophoresis (PFGE)
in DNA analysis, 328–329
in genetic mapping, 320, 328
and NF2 gene isolation, 341–342
and NF1 locus, 328

Recombination, of TSC/ABO/ABL, 265
Renal angiomyolipoma, 3–4, 36, 44–46, 71, 101, 109, 124, 196, 211, 214, 367
age-dependent expression of, 5
complications of, 107
prevalence of
with age, 42–43
in females, 5, 43
Renal carcinoma, 43, 101, 106
angiomyolipoma association with, 106
renal cysts association with, 106
TSC association with, 375
Renal cell carcinoma, 36, 41–42, 45, 61, 363
angiomyolipoma coexistence with, 41, 108
genes for, 334–336
oncocytoma coexistence with, 41
tumorigenesis of, 334
in VHL, 333–334, 336
Renal cysts, 36–46, 52, 106, 108, 124, *see also* Cystic disease
frequency of, 36
renal carcinoma coexistence with, 106
Renal tumors, in pulmonary TSC, 61
Renal ultrasound, in TSC evaluation, 285, 317
Restriction fragment-length polymorphism (RFLP)
and DNA analysis, 291–292
and DNA markers, 332, 339, 341
and human *EVI2*, 322
Retinal angioma, 363
Retinal hamartomas, 1–4, 17, 61, 66, 367, *see also* Phakomas; Retinal phakomas
diagnosis of
adenoma sebaceum and, 22
CT and, 22
evolution of, 20–21
histopathology of, 21–22
management of, 22–23
pigmentary changes in, 19–20
types of, 17
mulberry cluster tumor, 18–19, 21, 23
noncalcified tumor, 18, 23
transitional tumor, 19, 23
vascular changes in, 20
and visual loss, 21
Retinal phakomas, 124
in pulmonary TSC, 61
Retinitis pigmentosa, chromosome deletion in, 243
Retinoblastoma (RB), 23, 323
mendelian inheritance in, 215–216
tumorigenesis of, 334
and tumor suppression gene, 333
as two-hit mutation model, 165–167
Reverse genetics approach, 308–309, 355
in inherited disease investigations, 332–333
RFLP, *see* Restriction fragment-length polymorphism

Saturation mapping, and NF2 gene locus, 342
Schwannoma, 338, *see* Acoustic neuroma
and chromosome 22, 339
SEGA, *see* Subependymal giant cell astrocytoma
Seizures, *see also* Epilepsy
cortical tubers and, 13
and mental retardation, 14
in TSC, 2, 8–9, 12–15, 26, 55, 71, 228
SEN, *see* Subependymal nodules
Shagreen patches, 3–4, 29, 126, 228, 247, 367
in retinal hamartoma diagnosis, 22
Sickle-cell anemia, allelic heterogeneity in, 348
Somatic-cell hybrid mapping, of NF1 locus, 320–322, 328–329
Somatic mosaicism, 352
Southern blot analysis
of acoustic neuroma, 339
of DNA markers, 295
of hexabrachion gene, 224
of meningioma, 339
of NF1 region, 329
of NF2 gene, 342
Spinal muscular atrophy, 345
Subependymal giant cell astrocytoma (SEGA), 2, 81, 86, 124, 134, 136, 187, 213–214, 247
EM findings in, 141–147
hexabrachion-mediated neuronal migration and, 225
MRI characteristics of, 90–92
Subependymal nodules
age-dependent expression of, 5
Subependymal nodules (SEN), 1–2, 5, 81, 86–92, 112, 114, 119, 121, 124, 131–

137, 146, 187, 212–214, 246, 257, 279
CT detection of, 92
and neural crest, 164
in retinal hamartoma diagnosis, 22

Tay-Sachs disease, allelic heterogeneity in, 348
Transitional retinal hamartomas, 23
TSC, *see* Tuberous sclerosis complex
Tuberous Sclerosis Collaborative Study, 293, 308
Tuberous sclerosis complex (TSC)
ABL linkage to, 265, 267, 269, 271–272, 280, 304
abnormal FN in, 361–362
abnormal gene expression in, 228–241
ABO linkage to, 224, 257, 265–266, 271, 284, 292–295, 304–305, 316, 380, 384
age-dependent expression of, 5
aneurysms in, 3, 65–67
ataxia telangiectasia similarities to, 274, 279
autism in, 14–15, 372–373
brain tumors in, 378–379
c-abl gene linkage to, 224
cardiac involvement of, *see* Cardiac rhabdomyoma
and cell/tissue banking, 316
cellular neuropathology of, 140–147, 212–214
cerebral lesions histogenesis, 187–193
chromosomal abnormality in, 248–250
chromosome 9 linkage with, 258–263
chromosome 11 linkage with, 258–263
clinical features of, 367
CNS involvement of, 1–2, 81–92
CNS lesions in
giant cells in, 213–214
N-cells in, 214
spider cells in, 214
conjugated protein alterations in, 149–157
cytogenetic abnormality in, 243–254
description of, 1–4, 8, 26
diagnosis of
CCT scan for, 95–96, 98, 112–121, 285
CT for, 3, 8, 22, 52, 81–86, 101, 106–110, 126, 307
echocardiography for, 3, 50–56, 58, 96, 317, 365
EEG for, 8–15, 26, 28
MRI and, 8–15, 52, 86–92, 96, 112–121, 126, 285, 317, 365
radiologic imaging and, 123–124
ultrasonography and, 51, 96, 98, 101, 107–108, 110, 114, 285
diagnostic criteria for, 1–6, 14, 26–34, 50, 71, 123–124, 247, 257, 317
dysplasia in, 65, 137, 140, 147
electron microscopy findings in, 140–147
enamel pitting in, 367–368
epidemiology of, 125–127
epilepsy in, 8–9, 12–15, 17, 43, 72, 126, 228, 265, 367
familial, 380
gastrointestinal manifestations of, 71–79
gene carrier diagnosis in, 112–121
gene expression and, 147
gene locus for, *see* Chromosome 9; Chromosome 11; Chromosome 14; Chromosome 17; Chromosome 22
gene mapping for, 298–304
genetic counseling for, 30, 117–121, 126–127, 265, 271, 284, 365
germinal heterogeneity in, 349
hamartomas, *see under* Hamartomas
hepatic involvement of
imaging of, 108–110
heterogeneity in, 262, 265, 271–272, 344, *see also* Linkage analysis
history of, 1–2, 8, 17, 125
homogeneity of, 254, 258–263, 292–294
imaging of, *see* Computerized tomography; Echocardiography; Electroencephalography; Magnetic resonance
inheritance of, 112, 267
intracranial, 81–92
kidney involvement in, 1, 3, 36–46
angiomyolipomas in, 36, 42–46
renal cell carcinoma in, 36, 41–42, 45
renal cysts in, 36–41, 46
Klippel-Trenaunay syndrome coexistence with, 79, 94, 98
lesions in
pathogenesis of, 280–281
linkage of, *see also* Linkage analysis
lod scores and, 258–261
marker gene polymorphism and, 262
two-point lod scores for, 293
linkage studies in, 284–295
lung lesion origin in
cell surface receptors and, 280
mental retardation in, 1–2, 8, 12–15, 125–127, 142, 265
pathogenesis of, 8
mortality in, 375–376
mutation model for, 165–168, 192–193
mutations in, 126, 192, 225, 267, 274, 284, 354–359
N-cells in, 196–209
neural crest links with, 164–168
neurofibromatosis coexistence with, 71, 79, 94, 98

neurologic abnormalities in, 2, 125–127
neuropathology of, 128–138
neuropsychiatric aspects of, 8–15
neuropsychologic features of
EEG foci localization and, 8–15
MRI lesions and, 8–15
ophthalmic manifestations of, 1–4, 17–23, 61, 66, 367, *see also* Retinal hamartomas
pathogenesis of, 279–281, 317–318, 354–358
and ECM, 361–362
factors in, 280–281
pathophysiologic mechanisms in, 187–193
penetrance of, 1, 5–6, 192, 256–257, 263
phenotypes of, 1–6, 316–317
and mutation, 158
phenotypic expression in, 36
phenotypic heterogeneity in
chromosomal mutation and, 158
probability of
for genetic linkage studies, 365
psychiatric disorders in, 382–383
pulmonary involvement in, 3, 60–65
gender and, 94
imaging of, 94–95, 110
LAM in, 60, 64–65
pathologic features of, 61, 64–65
treatment of, 65
renal involvement in, 257
imaging, 98, 101, 106–108
skeletal manifestations of, 94
skin signs of, 1–5, *see also* Adenoma sebaceum; Facial angiofibroma; Forehead plaques; Hypomelanotic macules; Shagreen patches; Ungual fibroma
symptoms of, 2–4
tissue culture of
cell morphology in, 197–199
immunocytochemistry of, 199–202
understanding of, 354–360
vascular involvement of, 65–67, 98, 110
Wolff-Parkinson-White syndrome association with, 58, 60
Tuberous sclerosis complex (TSC) gene, 257–263, 274–275, 303–304, 372
expression of, 2–4
linkage, *see also* Linkage analysis
localization of, 265–272, 299–304, 310, 312
N-CAM gene identity as, 278–279
Tuberous sclerosis complex (TSC) support groups, 370–371
Tumorigenesis
of acoustic neuroma, 339
of meningioma, 339
two-hit model of, 215–216
for TSC, 216–217
Tumor suppressor gene
in hereditary cancer, 333
locus of, 334–336
Tumor syndromes, with mendelian inheritance, 215–216

Ultrasonography
angiomyolipoma monitoring by, 107–108
in cardiac patient evaluation, 110
and cardiac rhabdomyoma detection, 51
of hepatic hamartomas, 108
and TSC diagnosis, 114
and TSC screening, 96, 98, 101, 108, 110
Ungual fibroma, 3–4, 29, 46, 71, 124, 126, 211, 281, 367, *see also* Periungual fibroma
in retinal hamartoma diagnosis, 22

Van der Wode syndrome, chromosome deletion in, 243
Venezuelan Reference Pedigree
and chromosome 9 map, 292
and TSC-chromosome 9 linkage, 258
VHL, *see* Von Hippel-Lindau disease
Vimentin, in TSC cells, 202, 205, 212, 230, 232, 239, 372–373
Vitiligo, hypomelanotic macule simulation of, 26–28
Vogt's triad, 17, 257
Von Hippel-Lindau disease (VHL), 45
chromosome 3 and, 333–336, 363
clinical features of, 333
clinical phenotype of, 363–364
variability in, 363
gene locus of, 333–336
genetic counseling for, 363
genetic defect in
DNA linkage analysis of, 332–334
reverse genetics approach to, 332–335
RFLP studies of, 332–334
penetrance of, 333
renal cell carcinoma in, 333–336
tumorigenesis in, 333–336
tumors in, 333, 363
Von Recklinghausen's disease, *see* Neurofibromatosis 1

Wilms' tumor, mendelian inheritance in, 215–216
Wolff-Parkinson-White syndrome, TSC association with, 58, 60
Wood's light, in hypomelanotic macule diagnosis, 26–34, 50, 247, 360, 365